CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 76 enrolled
Drug / intervention
Ticagrelor 90mg +2 moredrug
Likely dose
Ticagrelor 90mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03649711
NCT03649711Phase 3Completed

A Mechanistic Study in Patients With Non-Dialysis Chronic Kidney Disease to Investigate Altered Platelet Response to Antiplatelet Therapy (CKD-Platelet Study)

University of Arkansas·interventional·Posted Aug 28, 2018·Updated Dec 29, 2022

In Brief

A Phase 3 clinical trial evaluating Ticagrelor 90mg, Clopidogrel 75mg, and 1 other intervention for Chronic Kidney Diseases and 2 related conditions. Completed, enrolled 76 participants across 2 sites.

Detailed Summary

This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys. In the first part of the study, half of CKD participants will be randomly assigned to ticagrelor and aspirin, while the other half will be assigned to clopidogrel and aspirin in a blinded fashion. The treatment duration will be two weeks. After recruiting CKD participants the investigator will recruit controls with normal kidney function that will receive only ticagrelor and aspirin for two weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedAug 28, 2018
Enrollment StartNov 1, 2018
Primary CompletionSep 2, 2021
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 7.8 years ago

Interventions

Ticagrelor 90mgdrug

Ticagrelor Pill

Clopidogrel 75mgdrug

Clopidogrel Pill and a matching placebo to conceal frequency

Aspirin 81 mgdrug

Aspirin Pill